Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers

Fineline Cube Apr 27, 2026
Company Drug

Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant

Fineline Cube Apr 27, 2026
Company Deals

Edding Pharma Aims for Fifth IPO Attempt on Hong Kong Stock Exchange

Fineline Cube Jun 25, 2023

China-based Edding Pharma is gearing up for its fifth attempt to hold an initial public...

Drug Policy / Regulatory

CDE Releases Guidelines for Clinical Trials of Stem Cell Therapies and Derived Products

Fineline Cube Jun 25, 2023

The Center for Drug Evaluation (CDE) has released a set of “Guidelines for Clinical Trial...

Company Drug

Sciwind Biosciences Leads China’s Anti-Obesity Drug Market with GLP-1 Analog Ecnoglutide

Fineline Cube Jun 25, 2023

Sino-US biotech Sciwind Biosciences Co., Ltd has positioned itself as a frontrunner in China’s race...

Drug Policy / Regulatory

CDE Releases Draft Guidelines for Antibody Drug Conjugate Research and Evaluation

Fineline Cube Jun 25, 2023

The Center for Drug Evaluation (CDE) has released a draft set of “Guiding Principles for...

Company Deals

Aureka Biotechnologies Secures $10 Million in Seed Funding for AI-Driven Biotechnology

Fineline Cube Jun 25, 2023

Aureka Biotechnologies Inc., a California-based artificial intelligence (AI)-empowered biotech company, has successfully raised USD 10...

Company Drug

Jiangsu Hengrui’s Camrelizumab Earns Full Approval for Advanced Hepatocellular Carcinoma in China

Fineline Cube Jun 21, 2023

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced the transition of its programmed death-1 (PD-1)...

Company Drug

Biocytogen Pharmaceuticals Receives CNIPA Patent for RenMab Human Antibody Mice Platform

Fineline Cube Jun 21, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced receiving a prestigious patent award...

Company Drug

BeiGene Initiates First-in-Human Trial for Next-Generation BCL-2 Inhibitor BGB-21447

Fineline Cube Jun 21, 2023

China-based BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the first patient dosing in...

Company Drug

Jiangsu Hengrui Pharmaceutials’ SHR-1209 for Hypercholesterolemia Accepted for NMPA Review

Fineline Cube Jun 21, 2023

China-based Jiangsu Hengrui Pharmaceutials (SHA: 600276) has announced that a market filing for its Category...

Company Drug

Minghui Pharmaceutical Achieves First Dosing Milestone in Phase I Studies for ADC Candidates

Fineline Cube Jun 21, 2023

China-based biotech Minghui Pharmaceutical Inc. has reported that the first dosing has been completed in...

Company Deals

Xiamen ITG Group and Fosun Health Collaborate on Big Health Industry Fund and Medical Device Commercialization

Fineline Cube Jun 21, 2023

China-based Xiamen ITG Group Co., Ltd. (SHA: 600755) and Shanghai Fosun Health Technology (Group) Co.,...

Company Medical Device

Australian Scleral Lens Epicon A Approved by China’s NMPA as 10th Novel Product

Fineline Cube Jun 21, 2023

Ruitai Bio’s Epicon A, a scleral lens product from Australia, has been approved by the...

Company Drug

CDE Considers Breakthrough Therapy Designation for Beijing Mabworks’ MIL162 and Amgen’s AMG 890

Fineline Cube Jun 21, 2023

The Center for Drug Evaluation (CDE) website indicates that China-based Beijing Mabworks Biotech Co., Ltd’s...

Company Drug

Fujian Cosunter Pharmaceutical’s COVID-19 Drug GST-HG171 Meets Primary Endpoint in Phase II/III Study

Fineline Cube Jun 21, 2023

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced that the pivotal Phase II/III...

Company Drug

Boehringer Ingelheim’s Spevigo on Track for Priority Review for GPP Flare Prevention in China

Fineline Cube Jun 21, 2023

Germany-based Boehringer Ingelheim’s (BI) interleukin-36 receptor (IL-36R)-targeted orphan drug, Spevigo (spesolimab), in subcutaneous injection form,...

Company Drug

Bio-Thera Solutions’ PD-1 Inhibitor BAT1308 Approved for Cervical Cancer Clinical Trials in China

Fineline Cube Jun 21, 2023

Bio-Thera Solutions Ltd (SHA: 688177) has announced that its programmed death-1 (PD-1) inhibitor, BAT1308, has...

Company

Pfizer to Establish Smart Medical Innovation Center in Hangzhou’s Qiantang District

Fineline Cube Jun 20, 2023

US pharmaceutical giant Pfizer (NSE: PFIZER) has announced a plan to establish a smart medical...

Company Legal / IP

Medivir AB Receives Chinese Patent Approval for Liver Cancer Treatment Fostroxacitabine Bralpamide

Fineline Cube Jun 20, 2023

Sweden-based Medivir AB (FRA: MVR0) has announced the approval of a patent in China for...

Company Deals

Shanghai Cell Therapy Group Partners with Nantong Federation for Comprehensive Health Services Platform

Fineline Cube Jun 20, 2023

Shanghai Cell Therapy Group has entered into a partnership with the Nantong Federation of Industry...

Company Deals

Huadong Medicine’s Subsidiary Perfect mRNA Biotechnology Partners with Yoltech Therapeutics

Fineline Cube Jun 20, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) subsidiary, Hangzhou Perfect mRNA Biotechnology Co., Ltd, has...

Posts pagination

1 … 503 504 505 … 657

Recent updates

  • CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers
  • Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant
  • Henlius Biotech Launches Phase II/III Trial in Australia for Triple Combination Therapy in Squamous NSCLC Featuring Novel Anti-EGFR Antibody Pimurutamab and Approved PD-1 Inhibitor HanSiZhuang
  • Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg
  • AstraZeneca Secures FDA Approval for Subcutaneous Saphnelo in Systemic Lupus Erythematosus After Addressing Supplemental Data Request
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers

Company Drug

Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant

Company Drug

Henlius Biotech Launches Phase II/III Trial in Australia for Triple Combination Therapy in Squamous NSCLC Featuring Novel Anti-EGFR Antibody Pimurutamab and Approved PD-1 Inhibitor HanSiZhuang

Company Drug

Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.